SURGICAL TREATMENT AND TRENDS IN DESMOID TUMORS

Similar documents
Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Radiotherapy in locally advanced & metastatic NSC lung cancer

Colocutaneous Fistula. Disclosures

COMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER

Thomas A. Kollmorgen, M.D. Oregon Urology Institute

Preoperative drainage is always indicated in malignant CBD strictures PRO. Horst Neuhaus Evangelisches Krankenhaus Düsseldorf, Germany

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Colorectal cancer. A guide for journalists on colorectal cancer and its treatment

Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy

AORTOENTERIC FISTULA. Mark H. Tseng MD Brooklyn VA Hospital February 11, 2005

Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS

Targeted Therapy What the Surgeon Needs to Know

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Frequently Asked Questions About Ovarian Cancer

Ching-Yao Yang, Yu-Wen Tien

Mesothelioma. Malignant Pleural Mesothelioma

The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006

Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?

Loco-regional Recurrence

How To Treat A Uterine Sarcoma

Clinical Indications and Results Following Chest Wall Resection

The Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum

Cancer of the Cardia/GE Junction: Surgical Options

How common is bowel cancer?

Kidney Cancer OVERVIEW

Overview of Gynaecologic Cancer

Laparoscopic Surgery of the Colon and Rectum (Large Intestine) A Simple Guide to Help Answer Your Questions

Image SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.

Report series: General cancer information

PSA Screening for Prostate Cancer Information for Care Providers

THYROID CANCER. I. Introduction

Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery

بسم هللا الرحمن الرحيم

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

Columbia University Mesothelioma Applied Research Foundation Mesothelioma Center

7. Prostate cancer in PSA relapse

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

Adjuvant Therapy for Breast Cancer: Questions and Answers

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Hepatocellular Carcinoma Treatment Decision Tree

Does my patient need more therapy after prostate cancer surgery?

The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases

PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande

Early-stage Breast Cancer Treatment: A Patient and Doctor Dialogue

Malignant pleural mesothelioma P/D vs. EPP

Colorectal Cancer Treatment

Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology

A Practical Guide to Advances in Staging and Treatment of NSCLC


Invasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

Brain Cancer. This reference summary will help you understand how brain tumors are diagnosed and what options are available to treat them.

Osteosarcoma: treatment beyond surgery

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

How To Treat Lung Cancer At Cleveland Clinic

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future

Open Ventral Hernia Repair

How To Treat A Cancer With A Radical

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

Lung Cancer Treatment Guidelines

How to treat early gastric cancer. Surgery

Epi procolon The Blood Test for Colorectal Cancer Screening

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Individual Prediction

Radiation Therapy in the Treatment of

LIVER TUMORS PROFF. S.FLORET

Medullary Renal Cell Carcinoma Case Report

RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?

PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Gallbladder Diseases and Problems

Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD

Facing Pancreatic Surgery? Learn about minimally invasive da Vinci Surgery

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE

Specialty Excellence Award and America s 100 Best Hospitals for Specialty Care Methodology Contents

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD

MesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology

By Anne C. Travis, M.D., M.Sc. and John R. Saltzman, M.D., FACG Brigham and Women's Hospital Harvard Medical School Boston, MA

Oncology Quarterly. Corky and Kaylee Smith

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

LYMPHOMA IN DOGS. Diagnosis/Initial evaluation. Treatment and Prognosis

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

OBJECTIVES By the end of this segment, the community participant will be able to:

The Science behind Proton Beam Therapy

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.

Transcription:

SURGICAL TREATMENT AND TRENDS IN DESMOID TUMORS November 13, 2010 Marcovalerio Melis, MD Assistant Professor NYU School of Medicine New York, NY

Desmoid Tumors Rare, slow growing, mesenchymal proliferations Fibroblastic/myofibroblastic differentiation Increased activity of ß-catenin (CTNNB1 mutation) Benign Histologic appearence No metastatic potential Poorly circumscribed Invade and infiltrate surrounding tissues Local growth and invasion may result in: Pain Deformity Death when vital organ involved Functional impairement Ballo. Int J Radiat Oncol Biol Phys 1998 Slejfer. Eur J Cancer 2009

Heterogeneous Presentation Sporadic Extremity Trunk Intra-abdominal Pregnant or Post-Partum women Children Associated with Familial Adenomatous Polyposis

Unpredictable behavior Regression without treatement Multiple recurrence despite radical excisions and multi-modality treatement (25-60% at 5 years) Tumor related mortality is very rare Disfigurement and loss of function that may result from tumor progression or from treatment may be significant

Treatment Options Wheter, When and How to treat?? Surgery remains the mainstay of treatment for symptomatic desmoids arising in almost all sites Observation alone imatinib Chemotherapy Radiation Hormones Non-Steroidal Anti-Inflammatory COX-2 inhibitors

Surgical treatment Tailored based on Anatomic location Presentation What type of resection? How extensive a resection? The optimal therapeutic approach should differ based on the site and etiology of the desmoid should employ multimodality treatment Should aim to achieve the least morbidity without compromising the chance of definitive cure

Sporadic Extra-Abdominal (EA) Desmoids

Sporadic EA Desmoids 37-38% trunk 30-34% extremities 8-10% Head and Neck 5-24% Abdominal cavity 2-4 cases/million individuals 2 nd - 3 rd decade of life 60% in women Association with tissue trauma? Association with partum? C-section? Lev. J Clin Oncol 2007

Sporadic EA Desmoids Goal should be resection with negative margins Widely negative margins do not decrease recurrence rates compared to negative macroscopic margins but may compromise functional results Prognostic significance of microscopic positive margins is controversial Amputation reserved to non-functional limbs or other tumor-related complications Spear. Int J Radiat Oncol Biol Phys. 1998

Margin status and recurrences Author Year Wide or R0 R1 R2 Ballo 1998 27% 54% Bataini 1988 0% Easter 1989 76% Goy 1997 12% 68% Karakousis 1993 31% Lev 2007 16% 19% McKinnon 1989 5% 43% Merchant 1999 73% 75% Mirabell 1990 0% 22% 100% Posner 1989 15% 54% 50% Pritchard 1996 15% 50% Rao 1987 11% 84% Spear 1998 23% 44% 50%

Margin status and recurrences Author Patients Desmoid Year R0 R1 p Posner 131 All, FAP 1989 15% 54% < 0.01 Spear 107 1998 23% 44% 0.017 Ballo 189 All, FAP 1998 27% 54% < 0.01 Merchant 105 E/T 1999 73% 75% 0.51 Gronchi 203 E/T 2003 23% 26% 0.5 Lev 146 All 2007 16% 19% NS

Margin status and recurrences Author Patients Desmoid Year R0 R1 p Posner 131 All, FAP 1989 15% 54% < 0.01 Spear 107 1998 23% 44% 0.017 Ballo 189 All, FAP 1998 27% 54% < 0.01 Merchant 105 E/T 1999 73% 75% 0.51 Gronchi 203 E/T 2003 23% 26% 0.5 Lev 146 All 2007 16% 19% NS

Margin status and recurrences Positive margins per se influence subsequent adjuvant treatment Microscopically positive margins do not necessarily predict a recurrence A local recurrence does not necessarily portend to uncontrolled tumor growth For tumors that require extensive/disfiguring operation the focus should be on presevation of organ function and quality of life, rather than on striving for R0

Sporadic Intra-Abdominal (IA) Desmoids

IA Sporadic Desmoids Few sporadic desmoids (5-24%) are located in the abdominal cavity Most abdominal desmoids (74-87%) are sporadic Associated with definite mortality (complications of progression/treatment) Smith. Br J Surg 2000

IA Sporadic Desmoids Mesenteric desmoids usually too large for complete excision Resection of desmoids in proximity to mesenteric vessels may compromise viability of small bowel short bowel syndrome Mortality 3% Severe morbidity 13% Recurrence rate 11% Burke. Arch Patholl Lab Med 1990 Smith. Br J Surg 2000

IA Sporadic Desmoids Burke 1990 113 patients positive margins 47% (R1? R2?) 10 patients not resected 2 died of other causes 8 alive without evidence of disease Smith 2000 16 resected positive margins 68% local recurrence 37% 8 not resectable 10-year survival 73% (p = 0.73) Burke. Arch Patholl Lab Med 1990 Smith. Br J Surg 2000

IA Sporadic Desmoids No definitive information on influence of positive margins on recurrence/outcomes Chances of obtaining negative margins are low Heroic resections that endanger viability of the small intestine should be avoided

FAP-associated Desmoids

FAP-associated Desmoids 9-29% of FAP patient develop desmoids 850-fold frequency increase 75% intra-abdominal 82-86% develop after abdominal operation Clark. Br J Surg 1999 Gold. Ann Surg 2006

FAP-associated Desmoids Higher chance of complications Bowel obstruction 27% Ureteral obstruction 24% Bowel perforation 9% Entero-cutaneous fistula 4% Bleeding 4% Recurrence 41% Mortality 10-15% Clark. Br J Surg 1999 Gold. Ann Surg 2006 Slejfer. Eur J Cancer 2009

FAP-associated Desmoids Burke 1990 10 patients with FAP-IA desmoids operated on 90% had recurrence 60% Overall mortality 50% Surgical-related mortality Berk 1992 13/40 patients with FAP-IA operated on 85% had recurrence 53% desmoid-related mortality Burke. Am J Surg Pathol 1990 Berk. Can J Surg 1992

FAP-associated IA Desmoids Clark 1999 22/68 patients operated on for intra-abdominal 71% (10/14) had recurrence 37% (8/22) Surgical mortality 42% (6/14) Short bowel syndrome requiring longterm TPN Smith 2000 5 patients operated on for intra-abdominal 2 patients operated on 3 unresected death alive at 36 mo f/u Clark. Br J Surg 1999 Smith. Br J Surg 2000

FAP-associated IA Desmoids Resection is: Technically challenging Associated with high morbidity Frequently followed by early recurrence Unclear if negative margins would decrease recurrence rates Spontaneous regression documented in 4-17% Surgery should be restricted to complications and failure of non-operative treatment Melis 2008 Jones, Ann Surg 1986 Reitamo. Arch Surg 1983

Multi-Modality Treatment

Adjuvant Radiation (XRT) Post-Operative XRT might offset the adverse impact of positive margins on recurrence At least 3 recent retrospective review showed no benefit of adjuvant XRT, even when margin status was accounted for Complications (fibrosis, paresis, edema, fractures, second malignancies) in 23% patients Ineffective for IA or FAP desmoids Should not be used in children Ballo. J Clin Oncol 1999 Merchant. Cancer 1999 Gronchi. J Clin Oncol 2003 Lev. J Clin Oncol 2007

Definitive XRT Several series report recurrence rates comparable or lower than surgery Rapid resolution of the mass should not be expected Not an option if impending complication Neoadjuvant XRT Does not improve rates of resection with negative margins

Medical treatment Good option for FAP-associated, locally advanced or unresectable desmoids Chemotherapy Imatinib Anti-estrogens NSAIDS

Wait & See

What about No treatment? Bonvalot.. Eur J Surg Oncol 2008

What about No treatment? 3 spontaneous regressions (4% of primary desmoids) Fiore. Ann Surg Oncol 2009

Putting It All Together

Sporadic Extra-Abdominal Desmoids

Intra-Abdominal Desmoids

Take-Home messages We cannot predict which tumor would respond best to various treatments Therapeutic selection is challenging Watchful waiting is an option Surgery must be tailored to what is achievable in terms of negative margins while preserving function

Thank you!! Questions? marcovalerio.melis@nyumc.org